By Fineline Cube 
Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14 million) Series C1 financing round, alongside the initiation of its Series C2 funding. The round was led by Golden Venture Capital, with continued investment from existing shareholder Yuanbio Venture Capital.
Use of Proceeds
The funds will accelerate the global commercialization of ShuWen Bio’s first-in-class diagnostic products and expand R&D efforts to enrich its precision diagnostics portfolio for women’s health.
Company Profile
ShuWen Bio is an international company specializing in in vitro diagnostic (IVD) reagents for women’s health. It holds over 100 exclusive diagnostic patents and offers multiple first-in-class diagnostic products and services. The company has established a comprehensive suite of solutions in maternal-fetal medicine and breast cancer precision diagnostics.-Fineline Info & Tech